UCL-CUL Mont Godinne
Welcome,         Profile    Billing    Logout  
 7 Trials 
8 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vergote, Ignace B
INNOVATE-3, NCT03940196: Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / )

Completed
3
540
Europe, Canada, US, RoW
NovoTTF-100L(O), TTFields, Paclitaxel, Weekly Paclitaxel, Taxol
NovoCure Ltd.
Ovarian Cancer
05/23
05/23
NCT02822157 / 2015-005838-22: Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer

Active, not recruiting
2
160
Europe
Olaparib, Lynparza, carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly
Universitaire Ziekenhuizen Leuven, AstraZeneca
Ovarian Epithelial Cancer
07/21
07/23
NCT03340376 / 2016-000547-14: Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer

Active, not recruiting
2
48
Europe
Atezolizumab, Doxorubicin
Universitaire Ziekenhuizen KU Leuven, Roche Pharma AG
Cervical Cancer
09/25
09/25
D'hondt, Lionel
PEACE III, NCT02194842 / 2014-001787-36: Phase III Radium 223 mCRPC-

Active, not recruiting
3
446
Europe, Canada, RoW
Ra223, Enzalutamide
European Organisation for Research and Treatment of Cancer - EORTC, Bayer, Astellas Pharma Europe Ltd., UNICANCER, Canadian Urologic Oncology Group, Latin American Cooperative Oncology Group, Cancer Trials Ireland
Prostate Cancer
02/24
12/28
Tamarack, NCT05551117: A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

Hourglass Sep 2024 - Sep 2024 : Updated safety and efficacy data for mCRPC
Completed
2
192
Europe, US, RoW
vobramitamab duocarmazine 2.0 mg (Arm A), MGC018, vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine, Abiraterone, Enzalutamide
MacroGenics
Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma
07/24
01/25
NCT05920408 / 2022-001385-35: Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours

Terminated
1b/2a
6
Europe
EXS21546
Exscientia AI Limited, Biotrial
Advanced Solid Tumours
09/23
10/23
NCT06667960: A Study of JK06 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Recruiting
1/2
155
Europe
JK06
Salubris Biotherapeutics Inc
Solid Tumor
04/28
08/28
NCT05620134 / 2022-000339-21: Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Active, not recruiting
1/2
263
Europe
JK08, Pembrolizumab, Lenvatinib Pill
Salubris Biotherapeutics Inc, Salubris Biotherapeutics, Inc.
Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer, Melanoma, Colorectal Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Urothelial Carcinoma, Squamous Cell Carcinoma of Head and Neck, Luminal Breast Cancer, Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Gastric Adenocarcinoma, GastroEsophageal Cancer, Squamous Cell Carcinoma Skin, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma, Colorectal Adenocarcinoma, Epithelial Ovarian Cancer, Thyroid Cancer
10/25
02/26

Download Options